Clinical Scorecard: Effectiveness of Pharmacological Treatments in Pediatric Patients with Metabolic Dysfunction-Associated Steatotic Liver Disease: A Systematic Review and Network Meta-Analysis

At a Glance

Key Highlights

• Prevalence of MASLD is 7.6% in the general pediatric population and 34.2% in obesity clinics.
• Lifestyle modification is the cornerstone of MASLD management.
• Pharmacologic treatments like vitamin E, metformin, and orlistat show promise but lack universal acceptance; further research is needed.
• Current guidelines do not provide specific exercise prescriptions for MASLD management.
• The incidence of MASLD is projected to rise significantly by 2040.

Guideline-Based Recommendations

Diagnosis

• Diagnosis through medical imaging (ultrasonography, MRI) or liver biopsy.

Management

• Lifestyle modifications including dietary changes, weight reduction, and increased physical activity.

Monitoring & Follow-up

• Assessment of liver enzyme levels, lipid profiles, and histological outcomes; recommended intervals for monitoring should be specified.

Risks

• Key risk factors include obesity, type 2 diabetes, dyslipidemia, and sedentary lifestyles.

Patient & Prescribing Data

Pediatric patients diagnosed with MASLD.

Vitamin E, metformin, N-acetylcysteine, and orlistat are explored as adjuncts to lifestyle interventions; evidence supporting each treatment should be detailed.

Clinical Best Practices

• Emphasize lifestyle modifications as primary treatment.
• Consider pharmacologic therapies as adjuncts when lifestyle changes are insufficient.
• Regular monitoring of liver function and metabolic parameters is essential.
• Incorporate interdisciplinary approaches involving dietitians and pediatricians.

References

• Systematic Review and Network Meta-Analysis